Published in October 31st, 2010
Advertisements
No matter what happens with the biosimilar legislation, patent holders will have to go through their patent files carefully.
The current generic drug industry was born from the Hatch-Waxman Act of 1984. Among its creations, this Act accounts for a specialized form of patent litigation called Abbreviated New Drug Application (ANDA) litigation. The Act defined an abbreviated approval process for small molecule drugs’ generics; however, it didn’t establish a structure for approving follow-on biologics, known as biosimilars and generic biologics. The US Congress is now studying legislation to create such a structure. If this legislation is ratified, it will most probably create a patent litigation structure very different from the ANDA form.
Through modern technologies, biologic drugs are isolated from living matter or produced in living cells. Biologics vary from small molecule drugs in various ways related to safety and product variability, aspects that are critical for the definition of an approval process for follow-on biologics:
-They are large and complex molecules or mixes of molecules.
-They are produced in living cells, offering great potential for greater variability based on the precise host cells or organisms used to create them, the growth conditions for culturing them, and the purification methods employed to isolate the biologic from contaminants.
-They show distinctive safety issues, like the possibility of producing negative immune responses.
Biologics are so complex and variable that it is difficult to define an approval process. These characteristics prevent the implementation of a therapeutic equivalence standard similar to the one used for small molecule generic drugs in the Hatch-Waxman Act. As an alternative, the standards of biosimilarity and interchangeability in HR 1427 and HR 1548 are proposed.
HR 1427 defines biosimilar as “no clinically meaningful difference between the biological product and the reference product would be expected in terms of safety, purity, and potency if treatment were to be initiated with the biological product instead of the reference product”. HR 1548 requires that a follow-on biologic candidate exhibits biosimilarity “based upon data derived from: analytical studies that demonstrate that the biological product is highly similar to the reference product, from animal studies, and from clinical studies that are sufficient to demonstrate safety, purity and potency”.
In regards to interchangeability, both HR’s agree in that the biological product should be biosimilar to the reference one, and that the patient should go from one to the other without risk.
The similarity standards proposed pose new issues for patent litigations because there is no requirement that the follow-on biologic should be identical to the reference product. Follow-on biologic candidates can say that their biologic doesn’t infringe any patents covering the reference product or its manufacturing process, and generic manufacturers may obtain approval on the basis of biosimilarity or interchangeability: it gives the same results but is different enough. In addition, the manufacturer will probably try to make the product in a different way from the patented process, creating concerns about the follow-on biologic not being truly biosimilar or interchangeable. It will certainly be a challenge for the reference product manufacturer to protect its investment.
In chain reaction, these possibilities will increase litigation costs, due to testing and characterization of the biologics, inspections of sites, and declarations of those involved. There will be lots of pharmaceutical consulting for sure.
If you liked this article, tell all your friends about it. They’ll thank you for it. If you have a blog or website, you can link to it or even post it to your own site (don’t forget to mention www.smartconsultinggroup.com as the original source).
Nigel Smart is a pharmaceutical consulting with extensive experience in the biotechnology and pharmaceutical industry. With Denise Smart, he manages Smart Consulting Group. Visit their blog at www.smartconsultinggroup.com/blog
Related posts:
- FDA Resolves Compliance Issues With Drug/Device Combination ... Drug/device combination products raise compliance and regulatory issues in the pharmaceutical industry. On their own, each drug and device has their own specific type of marketing and good manufacturing practices regulation. However, when drugs and devices are combined together, they pose a new compliance question – how will this new combined product be regulated as [...]...
- Proposed FDA CGMP Regulations Impact Pharmaceutical and ... The biotech and pharmaceutical industries face new changes with proposed rules concerning cGMP (current good manufacturing practice) for combination products. The cGMP proposal (74 Fed. Reg. 48,423) by the FDA’s Office of Combination Products (OCP) won’t create brand-new requirements. However, this proposed rule clarifies confusion applied to devices, drugs and biological products that are used [...]...
- The History And The Story Of Generic Drugs Generic drugs The history and the story of generic drugs is very long. But as a layman, all we need to understand clearly is that these generic drugs are nothing but “general drugs” or you can say cheap representation of original drugs. Basically to make a drug requires years of research in the laboratory first [...]...
- FDA Approval For Natural Cures: Don’t Hold Your Breath It’s funny when you pick up any bottle containing a natural herb or supplement and read the little message at the bottom: “These statements have not been evaluated by the Food and Drug Administration.” Ever wonder when the FDA is going to get around to evaluating them? After all, they have only been used for [...]...
- Early Rheumatoid Arthritis: What Is The Best Treatment ... Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, inflammatory disorder characterized by joint inflammation and joint destruction. If left untreated or poorly treated, RA is associated with progressive functional disability, significant morbidity, and even increased mortality. What this means is that RA is not just a disease associated with painful stiff joints but a disease [...]...
- Watch Excess Fat Disappear With Revolutionary ZERONA Until now, everyone wishing to get rid of excess fat on their bodies had two options – grueling diets and workouts that might or might not work, or invasive weight-loss surgery and all the downtime that comes with it. But what would you say to someone who could offer you a way to literally remove [...]...
- You Don’t Know JAK About Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic, progressive, systemic, autoimmune disease characterized by joint inflammation and destruction, progressive disability and adverse psychological effects. This condition places significant health, psychological, emotional, and socioeconomic burdens on both the patient as well as society. There is currently no cure for RA. The purpose of therapy is to control disease [...]...
- Ultra Refined Fish Oils What to Watch Out For When you are shopping for ultra refined fish oil, you will see that supplements come in a variety of forms and concentrations. Some manufacturers add other ingredients to “enhance” the health benefits. They might even offer a free sample. But, before you fall for the advertising gimmicks, take a moment to learn about the things [...]...
- Looking for the Best Over the Counter Eye Wrinkle Cream? You might be looking for the best over the counter eye wrinkle cream, because you know that there is no prescription formula or maybe you thought that there was. Either way, the news is good. The less expensive drugstore variety creams may be just as good as anything created by a pharmaceutical company, as long [...]...
- Princeton University EHS The Environmental Health and Safety Office is to provide health and safety services to the University community through technical support information and training programs consulting services and periodic auditing of health and safety practices and regulatory compliance http://web.princeton.edu/sites/ehs/” rel=”nofollowVisit website...
Previous post:
«
Simple Steps On How to Remove BlackheadsNext post: Muscle Mass Training »